Early subcutaneous basal insulin with intravenous insulin infusion for diabetic ketoacidosis management: A systematic review and meta-analysis of randomised controlled trials. [PDF]
Diabetes Obes MetabAbstract Aims To evaluate the effectiveness and safety of early initiation of subcutaneous (SC) basal insulin in combination with intravenous insulin infusion (IVII), compared with IVII alone, for the management of diabetic ketoacidosis (DKA). Materials and Methods A systematic search of PubMed, Embase, Scopus, and the Cochrane Library was conducted to
Thammakosol K +4 more
europepmc +2 more sources
In vitro metabolic and mitogenic signaling of insulin glargine and its metabolites. [PDF]
PLoS ONE, 2010 BACKGROUND: Insulin glargine (Lantus) is a long-acting basal insulin analog that demonstrates effective day-long glycemic control and a lower incidence of hypoglycemia than NPH insulin.
Mark R Sommerfeld +6 more
doaj +1 more source
The management of type 2 diabetes with fixed‐ratio combination insulin degludec/liraglutide (IDegLira) versus basal‐bolus therapy (insulin glargine U100 plus insulin aspart): a short‐term cost‐effectiveness analysis in the UK setting [PDF]
, 2018 Aim: To evaluate the cost‐effectiveness of IDegLira versus basal‐bolus therapy (BBT) with insulin glargine U100 plus up to 4 times daily insulin aspart for the management of type 2 diabetes in the UK.
ADVANCE Collaborative Group +47 more
core +1 more source
Diabetes mellitus remission in a cat with pituitary-dependent hyperadrenocorticism after trilostane treatment [PDF]
, 2018 An 8-year-old male neutered Persian cat was presented with polyuria, polydipsia, polyphagia and muscle weakness associated with a 7 month history of diabetes mellitus (DM).
Adriana Cunha Muschner +4 more
core +3 more sources
Insulin glargine: pharmacokinetic and pharmacodynamic basis of clinical effect
Сахарный диабет, 2014 Glargine became the first long-acting insulin analogue. Glargine was designed to meet basal insulin requirements throughout the day with a single injection.
Vadim Valer'evich Klimontov +1 more
doaj +1 more source
Сахарный диабет, 2023 Initiation of insulin therapy with basal insulin analogues has become the standard of care for type 2 diabetes mellitus (T2DM). Timely administration of insulin allows not only to slow down the progression of type 2 diabetes, but also to reduce the ...
S. V. Nedogoda +4 more
doaj +1 more source
Journal of Pharmacology and Pharmacotherapeutics, 2012 Insulin glargine is a long acting novel recombinant human insulin analogue indicated to improve glycemic control, in adults and children with type 1 diabetes mellitus and in adults with type 2 diabetes mellitus. The time course of action of insulins including insulin glargine may vary between individuals and/or within the same individual.
Doğan, Fatma Sarı +3 more
openaire +3 more sources
Effect of insulin glargine on cardiovascular risk analysed by mean HRV [PDF]
, 2019 Type 2 diabetes mellitus is an insidious disease that is increasingly present in geriatric population [1]. The greatest difficulty is represented by glycaemic control in geriatric patients often not very compliant with diet therapy and drug therapy.
Apicella, G. +5 more
core +1 more source
Frontiers in Endocrinology, 2019 Our aim was to investigate whether human insulin (HI) or insulin glargine treatment could promote the proliferation of thyroid cells and determine the association between type 2 diabetes and thyroid disease.
Xiaoli Sheng +6 more
doaj +1 more source
Cardiovascular Diabetology, 2008 Objective Exenatide belongs to a new therapeutic class in the treatment of diabetes (incretin mimetics), allowing glucose-dependent glycaemic control in Type 2 diabetes.
Tetlow Anthony P +3 more
doaj +1 more source